AstraZeneca has started to move away from providing its Covid-19 vaccine to countries on a not-for-profit basis.
The drugs giant has signed a series of for-profit agreements for next year, and expects to make a modest income from the vaccine, it said.
The company had previously said it would only start to make money from the vaccine when Covid-19 was no longer a pandemic.
Its chief executive Pascal Soriot said the disease was becoming endemic.
The jab will continue to be supplied on a not-for-profit basis to poorer countries.
Mr Soriot had said previously: "We decided to provide it at no profit, because our top priority was to protect global health."
He told the BBC he had "absolutely no regrets" about not making a profit when competitors had been, despite having to deal with political criticism in various countries.
He said the vaccine, which was developed with the University of Oxford, had saved a million lives around the world.
"I absolutely don't regret it," Mr Soriot said. "We are proud as a company of the impact we have had - we've saved millions of hospitalisations. The [AstraZeneca] team continues to do a stellar job."
<<Print>>